Skip to main content

Table 4 Risk of the cardiorenal composite adjusted for potential confounders

From: Clinical impact of suboptimal RAASi therapy following an episode of hyperkalemia

 

Unadjusted

Adjusteda

HR (95% CI)b

p-value

HR (95% CI)b

p-value

US

 Discontinued

1.75 (1.56–1.97)

< 0.001

1.55 (1.38–1.75)

< 0.001

 Down-titrated

1.80 (1.47–2.20)

< 0.001

1.51 (1.24–1.86)

< 0.001

Japan

 Discontinued

1.36 (1.18–1.57)

< 0.001

1.24 (1.07–1.44)

0.005

 Down-titrated

1.37 (1.05–1.80)

0.021

1.25 (0.95–1.65)

0.105

  1. CI Confidence interval, HR Hazard ratio
  2. aAdjusted for age, sex, history of hyperkalemia, diabetes, heart failure, chronic kidney disease including stage, and baseline use of angiotensin-converting enzyme inhibitors; angiotensin receptor blockers, angiotensin receptor-neprilysin inhibitors, and mineralocorticoid receptor antagonists, respectively
  3. bRisk relative to maintained renin-angiotensin-aldosterone system inhibitor treatment
Back to article page

BMC Nephrology

ISSN: 1471-2369

Contact us